Cargando…

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)

Vildagliptin is an oral agent which is a member of a new class of hypoglycemic drugs, dipeptidylpeptidase-4 (DPP-4) inhibitors. This review presents the physicochemical properties of vildagliptin and assesses analysis methods for its estimation in substances, medicinal formulations, and biological m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polyakova, E. B., Sabirzyanov, D. R., Prozorova, N. A., Foteeva, A. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964380/ https://www.ncbi.nlm.nih.gov/pubmed/35370321 http://dx.doi.org/10.1007/s11094-022-02606-1

Ejemplares similares

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation
por: Attimarad, Mahesh, et al.
Publicado: (2021)

Spectrophotometric Methods for the Determination of Sitagliptin and Vildagliptin in Bulk and Dosage Forms
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury
por: Sherif, Iman O., et al.
Publicado: (2020)

Synthesis, Properties, and Biological Activity of Poly(1-vinyl-1,2,4-triazole) and Silver Nanocomposites Based on It
por: Prozorova, G. F., et al.
Publicado: (2022)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
por: Zhang, Qian, et al.
Publicado: (2017)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Acceleration of CRISPR/Cas9-Mediated Editing at Multiple Sites in the Saccharomyces cerevisiae Genome
por: Karpukhin, Alexey D., et al.
Publicado: (2023)

Development of Sensitive and Specific Analysis of Vildagliptin in Pharmaceutical Formulation by Gas Chromatography-Mass Spectrometry
por: Uçaktürk, Ebru
Publicado: (2015)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Vildagliptin-induced acute lung injury: a case report
por: Ohara, Nobumasa, et al.
Publicado: (2016)

Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
por: Sridhar, GR, et al.
Publicado: (2023)

Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
por: Lee, Chen-Hung, et al.
Publicado: (2022)

The Analysis of the Physicochemical Properties of Benzocaine Polymorphs
por: Paczkowska, Magdalena, et al.
Publicado: (2018)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects
por: Ito, Daisuke, et al.
Publicado: (2015)

Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation
por: Zebedin-Brandl, Eva, et al.
Publicado: (2019)

Cation Solvation and Physicochemical Properties of Ca Battery Electrolytes
por: Forero-Saboya, J. D., et al.
Publicado: (2019)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
por: Kozlovski, Plamen, et al.
Publicado: (2017)

Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
por: Suh, Sunghwan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8ktrnkg9lmfnidkeee5tdlcftn